
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursuant to the Prescription Drug User Fee Act (PDUFA) has been assigned a target action date for the FDA decision in late September 2025.
The BLA resubmission includes the primary set of analyses comparing overall survival for narsoplimab-treated patients to overall survival for an external control group of TA-TMA patients. Results of those analyses showed clinically meaningful and statistically significant improvements in survival associated with narsoplimab treatment. Also included in the resubmission are data describing survival in Omeros' expanded access program in which adult and pediatric TA-TMA patients were treated with narsoplimab.
Since resubmission of the BLA in late March, Omeros has received and is responding to information requests from FDA and expects an interactive review by FDA.
Omeros is also preparing a marketing authorization application (MAA) for narsoplimab in TA-TMA, which is targeted for submission to the European Medicines Agency later this quarter.
About Narsoplimab
Narsoplimab, also known as 'OMS721,' is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 has been demonstrated to leave intact the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. A biologics license application (BLA) for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is under review by the U.S. Food and Drug Administration (FDA) and the corresponding European marketing authorisation application (MAA) is being prepared for submission. FDA has granted narsoplimab breakthrough therapy and orphan drug designations for TA-TMA and orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant.
About Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA)
Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a significant and often lethal complication of stem cell transplantation. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an approximately 40-percent incidence of TA-TMA, and high-risk features may be present in up to 80 percent of these patients. In severe cases of TA-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae (e.g., dialysis) are common. There is no approved therapy or standard of care for TA-TMA.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. Zaltenibart, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for treatment of paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit www.omeros.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the 'safe harbor' created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'likely,' 'look forward to,' 'may,' 'objective,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'slate,' 'target,' 'will,' 'would' and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated review process and timing of FDA action on the resubmitted BLA for narsoplimab in the United States, the anticipated submission of a marketing authorization application with the EMA and the timing thereof, the prospects for obtaining FDA or EMA approval of narsoplimab in any indication, and expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the potential commercialization of narsoplimab if it is approved by FDA or the EMA, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in the narsoplimab BLA , inability to respond satisfactorily to information requests during regulatory review of the narsoplimab BLA or MAA, potential differences between the diagnostic criteria used in our pivotal trial and in the external registry, and whether FDA and the EMA determine the registry used in our statistical analysis is sufficiently representative of TA-TMA patients, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions,, our financial condition and results of operations, including our ability to raise additional capital for our operations on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading 'Risk Factors' in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 1, 2024.. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
Secure Online Access to GLP-1 Weight Loss Medications Like Semaglutide Now Available Nationwide Through PlushCare's Updated Virtual Health Platform San Francisco, June 10, 2025 (GLOBE NEWSWIRE) -- PlushCare, a leading virtual healthcare platform, has announced a significant upgrade to its online Weight Loss Program, enabling greater access to GLP-1-based prescription treatments such as semaglutide through board-certified physicians. This development marks a critical milestone in the company's mission to provide affordable, clinically supervised weight management across the United States. Accessible at the updated platform streamlines the process for eligible adults to consult with licensed physicians, receive lab work if necessary, and access customized treatment plans—all from the comfort of their homes. 'We're committed to making evidence-based weight loss solutions more accessible through modern telehealth,' said a PlushCare spokesperson. 'Our program is designed to connect people with experienced doctors who can evaluate eligibility for medications like GLP-1s and deliver a personalized plan that fits their health goals.' Expanded Features for 2025 The revamped Weight Loss Program now includes: Nationwide Access to medical providers via secure telehealth appointments Eligibility Evaluation for FDA-approved medications, including semaglutide Personalized Plans tailored to each user's metabolic profile Optional Lab Testing with integrated results for precision treatment Transparent Pricing with no insurance required The platform is optimized for mobile and desktop users, offering a seamless experience from appointment scheduling to prescription delivery. Addressing a Growing National Health Concern According to the CDC, over 40% of U.S. adults struggle with obesity, with rising demand for effective clinical support. PlushCare's integrated virtual care model delivers a scalable solution that removes traditional geographic and scheduling barriers. Patients can typically get started in under 15 minutes by completing an intake form and booking a same-day appointment with a licensed doctor. If clinically appropriate, a prescription is sent to their preferred pharmacy. About PlushCare PlushCare is a virtual primary care and mental health platform that connects patients with top U.S. medical professionals through its secure telehealth platform. With a commitment to quality care, convenience, and evidence-based treatment, PlushCare is redefining access to modern healthcare. For more information, visit Media Contact:PlushCare Media RelationsEmail: press@ 345 California Street, Suite 600, San Francisco, CA 94105, United States SOURCE: PlushCare Disclaimer: This release contains forward-looking statements and should not be considered medical advice. All treatments are subject to clinical evaluation and provider discretion. CONTACT: Email: press@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


The Hill
28 minutes ago
- The Hill
Trump administration vs. mRNA vaccines
The Big Story President Trump once heralded the speedy development of an mRNA vaccine, but his new administration is casting doubts and fostering speculation over their use. © AP The Department of Health and Human Services (HHS) in late May canceled $766 million awarded to Moderna through the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential mRNA vaccine for bird flu. This came soon after HHS Secretary Robert F. Kennedy Jr. announced COVID-19 mRNA vaccines would no longer be recommended for children and pregnant women, though the Centers for Disease Control and Prevention (CDC) kept the shot on its schedule of childhood vaccinations. The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted vaccines and even showing promise in cancer research. Trump called mRNA the 'gold standard' when he rolled out the first COVID-19 vaccines. In remarks in December 2020, the same month the first COVID-19 vaccines were deployed, Trump praised Operation Warp Speed's ability to develop a SARS-CoV-2 vaccine at a 'breakneck speed,' adding, 'the gold standard vaccine has been done in less than nine months.' According to Joseph Varon, president and chief medical officer of the Independent Medical Alliance, the concerns for mRNA vaccine skeptics are the expedited timeline and the conditions in which the COVID-19 vaccine was approved. 'The biggest concern is that this rushed treatment still remains in use, even under an Emergency Use Authorization in some cases. It needs to be sent back through proper studies and vetting,' Varon told The Hill. In a move that could prevent future mRNA vaccines from receiving approval, Kennedy on Tuesday announced he was removing every member of the independent panel advising the CDC on vaccines. In a Wall Street Journal op-ed, he wrote, 'A clean sweep is needed to re-establish public confidence in vaccine science.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Senators grill NIH director in budget hearing: 4 takeaways National Institutes of Health Director Jay Bhattacharya faced questions from senators during an Appropriations subcommittee hearing Tuesday, as the federal government agency has taken hits to its staffing levels and grant-making ability since under President Trump. Senators focused on the Trump administration's requested 2026 budget, which calls for cutting NIH's funding by $18 billion from 2025 levels. … States sue 23andMe over genetic data sales More than two dozen states, along with the District of Columbia, are suing biotechnology company 23andMe over plans to auction off personal genetic information without their customers' knowledge or consent. 'The Pitt' actor Noah Wyle to make push for health care workers at Capitol Noah Wyle is heading to the pit of political power, with a visit to Capitol Hill to push for funding for programs aimed at improving mental health services for health care workers. 'The Pitt' and former 'ER' star will touch down in Washington on Thursday to lead a panel discussion at the Cannon House Office Building focused on the 'daily mental health, financial, and bureaucratic challenges for … In Other News Branch out with a different read: Collins calls Kennedy's firing of vaccine experts 'excessive' Sen. Susan Collins (R-Maine) on Monday called Health and Human Services Secretary Robert F. Kennedy Jr.'s firing of all 17 experts on the U.S. Centers for Disease Control and Prevention's (CDC) vaccine panel 'excessive,' but she cautioned she needs to learn more about the decision. Kennedy announced the decision in an op-ed for The Wall Street Journal, catching many GOP lawmakers by surprise. 'I did not know that that had happened,' … Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: Judge declines to block Trump's Corporation for Public Broadcasting firings but allows board members to stay Correction: A previous version of this article gave incorrect names of the fired CPB board members. They are Laura Ross, Diane Kaplan and Thomas Rothman. … Read more Newsom asks judge for emergency intervention in Trump troop deployment in LA California Gov. Gavin Newsom (D) asked a federal judge to immediately intervene on Tuesday to limit President Trump's deployment of the National … Read more You're all caught up. See you tomorrow! Thank you for signing up! Subscribe to more newsletters here
Yahoo
an hour ago
- Yahoo
S&P 500 Gains & Losses Today: J.M. Smucker Stock Sinks, Tesla Shares Recover
The S&P 500 added 0.6% on Tuesday, June 10, 2025, as investors awaited developments in trade negotiations between the U.S. and China. Tesla shares moved higher as social media posts from CEO Elon Musk promoted the company's upcoming robotaxi launch. Declining sales of sweet baked goods weighed on the performance J.M. Smucker, and shares of the food maker U.S. equities indexes climbed Tuesday as trade representatives from the U.S. and China engaged in talks for a second straight day. Both the S&P 500 and the Nasdaq ended the session with gains of around 0.6%, while the Dow was up 0.3%. Read Investopedia's full coverage of the day's trading here. Intel (INTC) shares surged nearly 8%, gaining the most of any stock in the S&P 500. Shares of other semiconductor makers also moved higher as the U.S.-China talks bolstered hopes for looser export restrictions. Although Apple (AAPL) said it will end support next year for Mac computers built with Intel's processors, providing more evidence of the transitional period faced by the chipmaker, analysts have expressed confidence in the ability of CEO Lip-Bu Tan, who took the reins of in March, to drive a turnaround at Intel. Caesars Entertainment (CZR) shares jumped 5.7%. TD Cowen analysts reiterated a "buy" rating on the casino operator's stock, noting that the company's loyalty program has helped drive entertainment, food and beverage, and lodging revenues to supplement its traditional earnings from gaming operations. The analysts also pointed to potential growth in its digital business. Tesla (TSLA) stock also added 5.7% as social-media posts from CEO Elon Musk hinted at the impending launch of the company's autonomous ride hailing service in Austin, Texas. Tuesday's move higher extended a recovery for the stock that kicked into gear during the previous session as tensions appeared to ease between Musk and President Donald Trump. Warner Bros. Discovery (WBD) shares advanced 5%, a day after the media conglomerate announced plans to split into two companies. One entity will house Warner's TV and movie studios along with the HBO Max streaming service, while the other will be home to its cable channels and the Discovery+ streaming service. The stock initially surged following the Monday-morning announcement, gave back those gains to end Monday's session lower, and then rose again today. Food maker J.M. Smucker (SJM) reported lower-than-expected sales for its fiscal fourth quarter of 2025, and its profit guidance for fiscal 2026 also came in below expectations. The maker of Folgers coffee and Uncrustables handheld sandwiches said that volume/mix impacts contributed to a year-over-year decline in net sales, especially declines in dog treats and sweet baked goods. Smucker shares sank nearly 16%, losing the most of any S&P 500 stock on Tuesday. Universal Health Services (UHS) fell 2.9% on Tuesday, extending losses posted in the prior session after the hospital operator's chief financial officer discussed a decline in the volume of surgical procedures at its facilities. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data